Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials.

Heerspink HJL, Greene T, Tighiouart H, Gansevoort RT, Coresh J, Simon AL, Chan TM, Hou FF, Lewis JB, Locatelli F, Praga M, Schena FP, Levey AS, Inker LA; Chronic Kidney Disease Epidemiology Collaboration.

Lancet Diabetes Endocrinol. 2019 Jan 8. pii: S2213-8587(18)30314-0. doi: 10.1016/S2213-8587(18)30314-0. [Epub ahead of print]

PMID:
30635226
2.

Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies.

Coresh J, Heerspink HJL, Sang Y, Matsushita K, Arnlov J, Astor BC, Black C, Brunskill NJ, Carrero JJ, Feldman HI, Fox CS, Inker LA, Ishani A, Ito S, Jassal S, Konta T, Polkinghorne K, Romundstad S, Solbu MD, Stempniewicz N, Stengel B, Tonelli M, Umesawa M, Waikar SS, Wen CP, Wetzels JFM, Woodward M, Grams ME, Kovesdy CP, Levey AS, Gansevoort RT; Chronic Kidney Disease Prognosis Consortium and Chronic Kidney Disease Epidemiology Collaboration.

Lancet Diabetes Endocrinol. 2019 Jan 8. pii: S2213-8587(18)30313-9. doi: 10.1016/S2213-8587(18)30313-9. [Epub ahead of print]

PMID:
30635225
3.

New pharmacological strategies for protecting kidney function in type 2 diabetes.

Muskiet MHA, Wheeler DC, Heerspink HJL.

Lancet Diabetes Endocrinol. 2018 Dec 19. pii: S2213-8587(18)30263-8. doi: 10.1016/S2213-8587(18)30263-8. [Epub ahead of print] Review.

PMID:
30579729
4.

Effects of Dapagliflozin on Circulating Markers of Phosphate Homeostasis.

de Jong MA, Petrykiv SI, Laverman GD, van Herwaarden AE, de Zeeuw D, Bakker SJL, Heerspink HJL, de Borst MH.

Clin J Am Soc Nephrol. 2019 Jan 7;14(1):66-73. doi: 10.2215/CJN.04530418. Epub 2018 Dec 17.

PMID:
30559106
5.

Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL.

Clegg LE, Heerspink HJL, Penland RC, Tang W, Boulton DW, Bachina S, Fox RD, Fenici P, Thuresson M, Mentz RJ, Hernandez AF, Holman RR.

Diabetes Care. 2019 Feb;42(2):318-326. doi: 10.2337/dc18-1871. Epub 2018 Dec 6.

PMID:
30523029
6.

Competing-Risk Analysis of Death and End Stage Kidney Disease by Hyperkalaemia Status in Non-Dialysis Chronic Kidney Disease Patients Receiving Stable Nephrology Care.

Provenzano M, Minutolo R, Chiodini P, Bellizzi V, Nappi F, Russo D, Borrelli S, Garofalo C, Iodice C, De Stefano T, Conte G, Heerspink HJL, De Nicola L.

J Clin Med. 2018 Dec 1;7(12). pii: E499. doi: 10.3390/jcm7120499.

7.

Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers.

Heerspink HJL, Sjöström CD, Inzucchi SE, Hallow MK, Cain VA, Rossing P, Stefansson BV, Sartipy P.

Diabetes Obes Metab. 2018 Nov 9. doi: 10.1111/dom.13579. [Epub ahead of print]

PMID:
30414240
8.

Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial.

de Zeeuw D, Renfurm RW, Bakris G, Rossing P, Perkovic V, Hou FF, Nangaku M, Sharma K, Heerspink HJL, Garcia-Hernandez A, Larsson TE.

Lancet Diabetes Endocrinol. 2018 Dec;6(12):925-933. doi: 10.1016/S2213-8587(18)30289-4. Epub 2018 Nov 6.

PMID:
30413396
9.

ACCORDION: Ensuring That We Hear the Music Clearly.

Wong MG, Heerspink HJL, Perkovic V.

Clin J Am Soc Nephrol. 2018 Nov 7;13(11):1621-1623. doi: 10.2215/CJN.11370918. Epub 2018 Oct 25. No abstract available.

PMID:
30361334
10.

Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial.

Wanner C, Heerspink HJL, Zinman B, Inzucchi SE, Koitka-Weber A, Mattheus M, Hantel S, Woerle HJ, Broedl UC, von Eynatten M, Groop PH; EMPA-REG OUTCOME Investigators.

J Am Soc Nephrol. 2018 Nov;29(11):2755-2769. doi: 10.1681/ASN.2018010103. Epub 2018 Oct 12.

PMID:
30314978
11.

New clinical trial designs for establishing drug efficacy and safety in a precision medicine era.

Heerspink HJL, List J, Perkovic V.

Diabetes Obes Metab. 2018 Oct;20 Suppl 3:14-18. doi: 10.1111/dom.13417. Review.

12.

Precision medicine in diabetes and diabetic kidney disease: Regulatory considerations.

Mol PGM, Thompson A, Heerspink HJL, Leufkens HGM.

Diabetes Obes Metab. 2018 Oct;20 Suppl 3:19-23. doi: 10.1111/dom.13453. Review.

13.

Treating diabetic complications; from large randomized clinical trials to precision medicine.

Heerspink HJL, de Zeeuw D.

Diabetes Obes Metab. 2018 Oct;20 Suppl 3:3-5. doi: 10.1111/dom.13418. Review.

14.

Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial.

Muskiet MHA, Tonneijck L, Huang Y, Liu M, Saremi A, Heerspink HJL, van Raalte DH.

Lancet Diabetes Endocrinol. 2018 Nov;6(11):859-869. doi: 10.1016/S2213-8587(18)30268-7. Epub 2018 Oct 3.

PMID:
30292589
15.

Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; apost hoc analysis of the PLANET trials.

Idzerda NMA, Pena MJ, Parving HH, de Zeeuw D, Heerspink HJL.

Nephrol Dial Transplant. 2018 Sep 1. doi: 10.1093/ndt/gfy159. [Epub ahead of print]

PMID:
30184238
16.

Personalized medicine in diabetic kidney disease: a novel approach to improve trial design and patient outcomes.

Idzerda NMA, Pena MJ, Heerspink HJL.

Curr Opin Nephrol Hypertens. 2018 Nov;27(6):426-432. doi: 10.1097/MNH.0000000000000447.

PMID:
30095480
17.

Reclassification of chronic kidney disease patients for end-stage renal disease risk by proteinuria indexed to estimated glomerular filtration rate: multicentre prospective study in nephrology clinics.

Provenzano M, Chiodini P, Minutolo R, Zoccali C, Bellizzi V, Conte G, Locatelli F, Tripepi G, Del Vecchio L, Mallamaci F, Di Micco L, Russo D, Heerspink HJL, De Nicola L; Collaborative Study Group on the Conservative Treatment of CKD of the Italian Society of Nephrology.

Nephrol Dial Transplant. 2018 Jul 23. doi: 10.1093/ndt/gfy217. [Epub ahead of print]

PMID:
30053127
18.

Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.

Hallow KM, Greasley PJ, Helmlinger G, Chu L, Heerspink HJL, Boulton DW.

Am J Physiol Renal Physiol. 2018 Jul 18. doi: 10.1152/ajprenal.00202.2018. [Epub ahead of print]

PMID:
30019930
19.

N-terminal pro-brain natriuretic peptide (NT-proBNP) predicts the cardio-renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk.

Idzerda NMA, Persson F, Pena MJ, Brenner BM, Brunel P, Chaturvedi N, McMurray JJ, Parving HH, de Zeeuw D, Heerspink HJL.

Diabetes Obes Metab. 2018 Dec;20(12):2899-2904. doi: 10.1111/dom.13465. Epub 2018 Aug 5.

20.

Early Proteinuria Lowering by Angiotensin-Converting Enzyme Inhibition Predicts Renal Survival in Children with CKD.

van den Belt SM, Heerspink HJL, Gracchi V, de Zeeuw D, Wühl E, Schaefer F; ESCAPE Trial Group.

J Am Soc Nephrol. 2018 Aug;29(8):2225-2233. doi: 10.1681/ASN.2018010036. Epub 2018 Jun 21.

PMID:
29930161
21.

How to measure and monitor albuminuria in healthy toddlers?

van den Belt SM, Gracchi V, de Zeeuw D, Heerspink HJL.

PLoS One. 2018 Jun 21;13(6):e0199309. doi: 10.1371/journal.pone.0199309. eCollection 2018.

22.

Immune-unreactive urinary albumin as a predictor of cardiovascular events: the Hortega Study.

Martínez F, Pichler G, Ruiz A, Martín-Escudero JC, Chaves FJ, Gonzalez-Albert V, Tellez-Plaza M, Heerspink HJL, Zeeuw DDE, Redon J.

Nephrol Dial Transplant. 2018 May 16. doi: 10.1093/ndt/gfy087. [Epub ahead of print]

PMID:
29788140
23.

Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease.

Dekkers CCJ, Wheeler DC, Sjöström CD, Stefansson BV, Cain V, Heerspink HJL.

Nephrol Dial Transplant. 2018 Jul 1;33(7):1280. doi: 10.1093/ndt/gfy135. No abstract available.

24.

Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.

Heerspink HJL, Kosiborod M, Inzucchi SE, Cherney DZI.

Kidney Int. 2018 Jul;94(1):26-39. doi: 10.1016/j.kint.2017.12.027. Epub 2018 May 5. Review.

PMID:
29735306
25.

Negative effect of vitamin D on kidney function: a Mendelian randomization study.

Teumer A, Gambaro G, Corre T, Bochud M, Vollenweider P, Guessous I, Kleber ME, Delgado GE, Pilz S, März W, Barnes CLK, Joshi PK, Wilson JF, de Borst MH, Navis G, van der Harst P, Heerspink HJL, Homuth G, Endlich K, Nauck M, Köttgen A, Pattaro C, Ferraro PM.

Nephrol Dial Transplant. 2018 Dec 1;33(12):2139-2145. doi: 10.1093/ndt/gfy074.

PMID:
29718335
26.

Trial Design Innovations to Accelerate Therapeutic Advances in Chronic Kidney Disease: Moving from Single Trials to an Ongoing Platform.

Heerspink HJL, Perkovic V.

Clin J Am Soc Nephrol. 2018 Jun 7;13(6):946-948. doi: 10.2215/CJN.01290118. Epub 2018 Apr 26. No abstract available.

PMID:
29700075
27.

Improving the prognosis of patients with severely decreased glomerular filtration rate (CKD G4+): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Eckardt KU, Bansal N, Coresh J, Evans M, Grams ME, Herzog CA, James MT, Heerspink HJL, Pollock CA, Stevens PE, Tamura MK, Tonelli MA, Wheeler DC, Winkelmayer WC, Cheung M, Hemmelgarn BR; Conference Participants.

Kidney Int. 2018 Jun;93(6):1281-1292. doi: 10.1016/j.kint.2018.02.006. Epub 2018 Apr 12.

28.

Predicting timing of clinical outcomes in patients with chronic kidney disease and severely decreased glomerular filtration rate.

Grams ME, Sang Y, Ballew SH, Carrero JJ, Djurdjev O, Heerspink HJL, Ho K, Ito S, Marks A, Naimark D, Nash DM, Navaneethan SD, Sarnak M, Stengel B, Visseren FLJ, Wang AY, Köttgen A, Levey AS, Woodward M, Eckardt KU, Hemmelgarn B, Coresh J.

Kidney Int. 2018 Jun;93(6):1442-1451. doi: 10.1016/j.kint.2018.01.009. Epub 2018 Mar 29. Erratum in: Kidney Int. 2018 Nov;94(5):1025-1026.

PMID:
29605094
29.

Baseline characteristics and enrichment results from the SONAR trial.

Heerspink HJL, Andress DL, Bakris G, Brennan JJ, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray J, Perkovic V, Tobe S, Wigderson M, Yi T, Parving HH, de Zeeuw D.

Diabetes Obes Metab. 2018 Aug;20(8):1829-1835. doi: 10.1111/dom.13315. Epub 2018 May 1.

30.

Determining the optimal dose of atrasentan by evaluating the exposure-response relationships of albuminuria and bodyweight.

Koomen JV, Stevens J, Mostafa NM, Parving HH, de Zeeuw D, Heerspink HJL.

Diabetes Obes Metab. 2018 Aug;20(8):2019-2022. doi: 10.1111/dom.13312. Epub 2018 May 1.

31.

New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors.

Dekkers CCJ, Gansevoort RT, Heerspink HJL.

Curr Diab Rep. 2018 Mar 27;18(5):27. doi: 10.1007/s11892-018-0992-6. Review.

32.

Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers.

Dekkers CCJ, Petrykiv S, Laverman GD, Cherney DZ, Gansevoort RT, Heerspink HJL.

Diabetes Obes Metab. 2018 Aug;20(8):1988-1993. doi: 10.1111/dom.13301. Epub 2018 Apr 23.

33.

Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy.

Heerspink HJL, Andress DL, Bakris G, Brennan JJ, Correa-Rotter R, Dey J, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray J, Perkovic V, Tobe S, Wigderson M, Parving HH, de Zeeuw D.

Diabetes Obes Metab. 2018 Jun;20(6):1369-1376. doi: 10.1111/dom.13245. Epub 2018 Mar 9.

34.

Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study.

Chin MP, Bakris GL, Block GA, Chertow GM, Goldsberry A, Inker LA, Heerspink HJL, O'Grady M, Pergola PE, Wanner C, Warnock DG, Meyer CJ.

Am J Nephrol. 2018;47(1):40-47. doi: 10.1159/000486398. Epub 2018 Jan 18.

35.

Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease.

Dekkers CCJ, Wheeler DC, Sjöström CD, Stefansson BV, Cain V, Heerspink HJL.

Nephrol Dial Transplant. 2018 Nov 1;33(11):2005-2011. doi: 10.1093/ndt/gfx350.

36.

Individual variability in response to renin angiotensin aldosterone system inhibition predicts cardiovascular outcome in patients with type 2 diabetes: A primary care cohort study.

Apperloo EM, Pena MJ, de Zeeuw D, Denig P, Heerspink HJL.

Diabetes Obes Metab. 2018 Jun;20(6):1377-1383. doi: 10.1111/dom.13226. Epub 2018 Feb 20.

37.

Renoprotective RAAS inhibition does not affect the association between worse renal function and higher plasma aldosterone levels.

Gant CM, Laverman GD, Vogt L, Slagman MCJ, Heerspink HJL, Waanders F, Hemmelder MH, Navis G; Holland Nephrology Study (HONEST) Network.

BMC Nephrol. 2017 Dec 20;18(1):370. doi: 10.1186/s12882-017-0789-x.

38.

The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics.

Jardine MJ, Mahaffey KW, Neal B, Agarwal R, Bakris GL, Brenner BM, Bull S, Cannon CP, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Levin A, Pollock C, Wheeler DC, Xie J, Zhang H, Zinman B, Desai M, Perkovic V; CREDENCE study investigators.

Am J Nephrol. 2017 Dec 13;46(6):462-472. doi: 10.1159/000484633. [Epub ahead of print]

39.

Longitudinal Estimated GFR Trajectories in Patients With and Without Type 2 Diabetes and Nephropathy.

Weldegiorgis M, de Zeeuw D, Li L, Parving HH, Hou FF, Remuzzi G, Greene T, Heerspink HJL.

Am J Kidney Dis. 2018 Jan;71(1):91-101. doi: 10.1053/j.ajkd.2017.08.010. Epub 2017 Nov 16.

PMID:
29153995
40.

Prediction of Chronic Kidney Disease Stage 3 by CKD273, a Urinary Proteomic Biomarker.

Pontillo C, Zhang ZY, Schanstra JP, Jacobs L, Zürbig P, Thijs L, Ramírez-Torres A, Heerspink HJL, Lindhardt M, Klein R, Orchard T, Porta M, Bilous RW, Charturvedi N, Rossing P, Vlahou A, Schepers E, Glorieux G, Mullen W, Delles C, Verhamme P, Vanholder R, Staessen JA, Mischak H, Jankowski J.

Kidney Int Rep. 2017 Nov;2(6):1066-1075. doi: 10.1016/j.ekir.2017.06.004.

41.

Heart failure and inflammation-related biomarkers as predictors of new-onset diabetes in the general population.

Suthahar N, Meijers WC, Brouwers FP, Heerspink HJL, Gansevoort RT, van der Harst P, Bakker SJL, de Boer RA.

Int J Cardiol. 2018 Jan 1;250:188-194. doi: 10.1016/j.ijcard.2017.10.035. Epub 2017 Oct 16.

42.

Pooled Analysis of Multiple Crossover Trials To Optimize Individual Therapy Response to Renin-Angiotensin-Aldosterone System Intervention.

Petrykiv SI, Laverman GD, Persson F, Vogt L, Rossing P, de Borst MH, Gansevoort RT, de Zeeuw D, Heerspink HJL.

Clin J Am Soc Nephrol. 2017 Nov 7;12(11):1804-1813. doi: 10.2215/CJN.00390117. Epub 2017 Oct 11. Review.

43.

Is Chronic Dialysis the Right Hard Renal End Point To Evaluate Renoprotective Drug Effects?

Weldegiorgis M, de Zeeuw D, Dwyer JP, Mol P, Heerspink HJL.

Clin J Am Soc Nephrol. 2017 Oct 6;12(10):1595-1600. doi: 10.2215/CJN.09590916. Epub 2017 Sep 18.

44.

Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial.

Webb DJ, Coll B, Heerspink HJL, Andress D, Pritchett Y, Brennan JJ, Houser M, Correa-Rotter R, Kohan D, Makino H, Perkovic V, Remuzzi G, Tobe SW, Toto R, Busch R, Pergola P, Parving HH, de Zeeuw D.

Drugs R D. 2017 Sep;17(3):441-448. doi: 10.1007/s40268-017-0201-0.

45.

Renal trials in diabetes need a platform: time for a global approach?

de Zeeuw D, Heerspink HJL, Jardine M, Perkovic V.

Lancet Diabetes Endocrinol. 2018 May;6(5):356-358. doi: 10.1016/S2213-8587(17)30263-2. Epub 2017 Aug 7. No abstract available.

PMID:
28797748
46.

Does SGLT2 inhibition with dapagliflozin overcome individual therapy resistance to RAAS inhibition?

Petrykiv S, Laverman GD, de Zeeuw D, Heerspink HJL.

Diabetes Obes Metab. 2018 Jan;20(1):224-227. doi: 10.1111/dom.13057. Epub 2017 Aug 8.

PMID:
28685934
47.

SGLT2 inhibition: a new era in renoprotective medicine?

Muskiet MHA, Heerspink HJL, van Raalte DH.

Lancet Diabetes Endocrinol. 2017 Aug;5(8):569-571. doi: 10.1016/S2213-8587(17)30222-X. Epub 2017 Jun 27. No abstract available. Erratum in: Lancet Diabetes Endocrinol. 2017 Aug;5(8):e5.

PMID:
28666776
48.

Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy.

Levin A, Tonelli M, Bonventre J, Coresh J, Donner JA, Fogo AB, Fox CS, Gansevoort RT, Heerspink HJL, Jardine M, Kasiske B, Köttgen A, Kretzler M, Levey AS, Luyckx VA, Mehta R, Moe O, Obrador G, Pannu N, Parikh CR, Perkovic V, Pollock C, Stenvinkel P, Tuttle KR, Wheeler DC, Eckardt KU; ISN Global Kidney Health Summit participants.

Lancet. 2017 Oct 21;390(10105):1888-1917. doi: 10.1016/S0140-6736(17)30788-2. Epub 2017 Apr 20. Review.

PMID:
28434650
49.

Predictive Properties of Biomarkers GDF-15, NTproBNP, and hs-TnT for Morbidity and Mortality in Patients With Type 2 Diabetes With Nephropathy.

Bidadkosh A, Lambooy SPH, Heerspink HJ, Pena MJ, Henning RH, Buikema H, Deelman LE.

Diabetes Care. 2017 Jun;40(6):784-792. doi: 10.2337/dc16-2175. Epub 2017 Mar 24.

PMID:
28341782
50.

Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function.

Petrykiv S, Sjöström CD, Greasley PJ, Xu J, Persson F, Heerspink HJL.

Clin J Am Soc Nephrol. 2017 May 8;12(5):751-759. doi: 10.2215/CJN.10180916. Epub 2017 Mar 16.

Supplemental Content

Loading ...
Support Center